Skip to main content
Sign In

Colorado Pulmonary-Alcohol Research Consortium (CoPARC)


About CoPARC


Pneumonia adversely affects the health of 20 million individuals in the US with alcohol use disorders (AUDs), including alcohol abuse and alcohol dependence. Pneumonia in these individuals is oftentimes more severe, and associated with frank respiratory failure, requiring intensive care. In this country, the numbers of individuals with AUDs who die from bacterial pneumonia annually approximate those due to more widely acknowledged alcohol-related conditions, including cirrhosis, trauma, and pancreatitis. Investigators have begun to unravel the mechanisms contributing to the increased susceptibility to alcohol-associated pneumonia through the development of animal model and small-scale human investigations. Unfortunately, translation of these discoveries to clinical trials in human subjects has been noticeably deficient. To develop new interventions for individuals with AUDs that decrease their predisposition for pneumonia, with the support of the National Institute on Alcoholism and Alcohol Abuse, we have developed the Colorado Pulmonary Alcohol Research Consortium (CoPARC) to conduct translational investigations to complement and extend basic science observations. The goal of CoPARC is to serve as a readily accessible biorepository of data and clinical samples from subjects with alcohol use disorders and controls. While our primary focus is on pulmonary processes affected by alcohol, we hope to extend our resources to support the research in other organ systems that contribute to critical illness in these individuals.

How can CoPARC help you?

  • biorepository of specimens/data from otherwise healthy subjects with alcohol abuse and dependence, who are otherwise healthy, and matched controls
  • biorepository of specimens/data from patients with burn injury, both with and without an alcohol consumption history
  • consortium of researchers with basic and clinical research experience in the field of alcohol-related pulmonary diseases to aid in experimental design and collaboration


CoPARC is supported by funding from NIH/NIAAA grant number R24 AA019661 with additional support from NIH/NCRR Colorado grant number CTSI UL1 RR025780.